Viking Therapeutics Inc (NASDAQ:VKTX) – Feltl & Co. boosted their FY2016 earnings per share estimates for shares of Viking Therapeutics in a note issued to investors on Monday. Feltl & Co. analyst B. Haynor now anticipates that the brokerage will post earnings of ($0.92) per share for the year, up from their prior estimate of ($0.96). Feltl & Co. also issued estimates for Viking Therapeutics’ Q4 2016 earnings at ($0.19) EPS, Q2 2017 earnings at ($0.28) EPS, Q3 2017 earnings at ($0.26) EPS, Q4 2017 earnings at ($0.22) EPS, FY2017 earnings at ($1.02) EPS and FY2020 earnings at $7.51 EPS.

A number of other analysts have also weighed in on VKTX. Maxim Group set a $5.00 price objective on Viking Therapeutics and gave the company a “buy” rating in a research note on Friday, November 11th. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Viking Therapeutics in a research note on Sunday, September 18th. Finally, Laidlaw dropped their price objective on Viking Therapeutics from $20.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, August 11th.

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics (NASDAQ:VKTX) opened at 1.17 on Wednesday. The stock’s market capitalization is $22.55 million. The firm’s 50-day moving average is $1.16 and its 200-day moving average is $1.27. Viking Therapeutics has a 12-month low of $0.94 and a 12-month high of $5.17.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.01.

An institutional investor recently raised its position in Viking Therapeutics stock. Sio Capital Management LLC raised its position in shares of Viking Therapeutics Inc (NASDAQ:VKTX) by 53.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 849,905 shares of the company’s stock after buying an additional 295,523 shares during the period. Viking Therapeutics makes up approximately 0.8% of Sio Capital Management LLC’s holdings, making the stock its 24th largest position. Sio Capital Management LLC owned about 4.41% of Viking Therapeutics worth $1,191,000 at the end of the most recent reporting period.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

5 Day Chart for NASDAQ:VKTX

Receive News & Stock Ratings for Viking Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc and related stocks with our FREE daily email newsletter.